NCT03758404View on ClinicalTrials.gov

Gene Therapy for Achromatopsia (CNGA3)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

August 12, 2019

Primary Completion Date

June 10, 2021

Study Completion Date

June 10, 2021

Conditions
Achromatopsia
Interventions
BIOLOGICAL

adeno-associated virus vector AAV- CNGA3

Adeno-associated virus (AAV) gene therapy for defects in CNGA3 gene

Trial Locations (2)

48105

Kellogg Eye Center, Ann Arbor

EC1V 2PD

Moorfields Eye Hospital NHS Foundation Trust, London

All Listed Sponsors
collaborator

Janssen Research & Development, LLC

INDUSTRY

lead

MeiraGTx UK II Ltd

INDUSTRY

NCT03758404 - Gene Therapy for Achromatopsia (CNGA3) | Biotech Hunter | Biotech Hunter